Literature DB >> 21249472

Prognostic value of C-reactive protein in chronic obstructive pulmonary disease.

Massimo Miniati1, Simonetta Monti, Matteo Bottai, Franca Cocci, Edo Fornai, Valter Lubrano.   

Abstract

To establish whether C-reactive protein (CRP) is an independent predictor of all-cause mortality and hospitalization in chronic obstructive pulmonary disease (COPD), we followed 200 patients with COPD and 201 age- and gender -matched controls for a median time of 4.2 years (range, 0.2-5.1 years). Airflow obstruction was rated moderate if forced expiratory volume in one second (FEV(1)) was 50-69% of the predicted value, or severe if FEV(1) was <50%. The CRP level was categorized as low (≤3 mg/L) or high (>3 mg/L). The hazard of death was estimated by a proportional hazard regression model, using controls with low CRP as the reference category. Fifty subjects died: 41 (21%) among the COPD and 9 (4%) among the controls (p < 0.0001). The hazard of death in moderate COPD was not significantly higher than in the reference category, independently of the CRP level. In severe COPD with a low CRP, the hazard of death is 3.4 times higher than in the reference category (p = 0.008); in severe COPD and a high CRP it is 9.6 times higher (p < 0.0001). The rate of hospitalization in COPD patients with a high CRP is 1.9 times higher than in those with a low CRP [95% confidence interval (CI), 1.2-3.2]. In severe COPD, it is 6.9 times higher than in moderate COPD (95% CI, 3.8-12.7). A high CRP level is a significant amplifier of the risk of death only in severe COPD. The degree of airflow obstruction is a strong independent predictor of COPD-related outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21249472     DOI: 10.1007/s11739-011-0520-z

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  22 in total

1.  ROENTGENOLOGIC CRITERIA FOR THE RECOGNITION OF NONSYMPTOMATIC PULMONARY EMPHYSEMA. CORRELATION BETWEEN ROENTGENOLOGIC FINDINGS AND PULMONARY PATHOLOGY.

Authors:  S SUTINEN; A J CHRISTOFORIDIS; G A KLUGH; P C PRATT
Journal:  Am Rev Respir Dis       Date:  1965-01

2.  Standardisation of the single-breath determination of carbon monoxide uptake in the lung.

Authors:  N Macintyre; R O Crapo; G Viegi; D C Johnson; C P M van der Grinten; V Brusasco; F Burgos; R Casaburi; A Coates; P Enright; P Gustafsson; J Hankinson; R Jensen; R McKay; M R Miller; D Navajas; O F Pedersen; R Pellegrino; J Wanger
Journal:  Eur Respir J       Date:  2005-10       Impact factor: 16.671

3.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

4.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.

Authors:  P W Jones; F H Quirk; C M Baveystock; P Littlejohns
Journal:  Am Rev Respir Dis       Date:  1992-06

5.  C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease.

Authors:  Morten Dahl; Jørgen Vestbo; Peter Lange; Stig E Bojesen; Anne Tybjaerg-Hansen; Børge G Nordestgaard
Journal:  Am J Respir Crit Care Med       Date:  2006-10-19       Impact factor: 21.405

6.  Reference spirometric values using techniques and equipment that meet ATS recommendations.

Authors:  R O Crapo; A H Morris; R M Gardner
Journal:  Am Rev Respir Dis       Date:  1981-06

7.  Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.

Authors:  Don D Sin; Paige Lacy; Ernest York; S F Paul Man
Journal:  Am J Respir Crit Care Med       Date:  2004-06-30       Impact factor: 21.405

8.  Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD.

Authors:  S Chappell; L Daly; K Morgan; T Guetta-Baranes; J Roca; R Rabinovich; J Lotya; A B Millar; S C Donnelly; V Keatings; W MacNee; J Stolk; P S Hiemstra; M Miniati; S Monti; C M O'Connor; N Kalsheker
Journal:  Eur Respir J       Date:  2008-07-09       Impact factor: 16.671

9.  The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease.

Authors:  Don D Sin; S F Paul Man; Darcy D Marciniuk; Gordon Ford; Mark FitzGerald; Eric Wong; Ernest York; Rajesh R Mainra; Warren Ramesh; Lyle S Melenka; Eric Wilde; Robert L Cowie; Dave Williams; Wen Q Gan; Roxanne Rousseau
Journal:  Am J Respir Crit Care Med       Date:  2008-02-28       Impact factor: 21.405

10.  Value of chest radiography in phenotyping chronic obstructive pulmonary disease.

Authors:  M Miniati; S Monti; J Stolk; G Mirarchi; F Falaschi; R Rabinovich; C Canapini; J Roca; K F Rabe
Journal:  Eur Respir J       Date:  2007-12-05       Impact factor: 16.671

View more
  8 in total

1.  C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure.

Authors:  Funda Aksu; Nermin Capan; Kurtuluş Aksu; Ruhsar Ofluoğlu; Sema Canbakan; Bünyamin Yavuz; Kadir Okhan Akin
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  Correlation between decrease of CRP and resolution of airway inflammatory response, improvement of health status, and clinical outcomes during severe acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Ying Liang; Chun Chang; Hong Zhu; Ning Shen; Bei He; Wanzhen Yao
Journal:  Intern Emerg Med       Date:  2015-03-31       Impact factor: 3.397

3.  Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Levent Cem Mutlu; Nejat Altintas; Murat Aydin; Feti Tulubas; Mustafa Oran; Volkan Kucukyalin; Gizem Kaplan; Ahmet Gurel
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

4.  Classification of Exacerbation Frequency in the COPDGene Cohort Using Deep Learning With Deep Belief Networks.

Authors:  Jun Ying; Joyita Dutta; Ning Guo; Chenhui Hu; Dan Zhou; Arkadiusz Sitek; Quanzheng Li
Journal:  IEEE J Biomed Health Inform       Date:  2016-12-21       Impact factor: 5.772

5.  C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease.

Authors:  Zai-Chun Deng; Peng Zhao; Chao Cao; Shi-Fang Sun; Feng Zhao; Chao-Yue Lu; Hong-Ying Ma
Journal:  Exp Ther Med       Date:  2013-12-09       Impact factor: 2.447

6.  Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.

Authors:  Aziz Gumus; Nejat Altintas; Halit Cinarka; Aynur Kirbas; Muge Hazıroglu; Mevlut Karatas; Unal Sahin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-02-13

7.  Predictors of mortality in COPD exacerbation cases presenting to the respiratory intensive care unit.

Authors:  Yang Cao; Zhenzhen Xing; Huanyu Long; Yilin Huang; Ping Zeng; Jean-Paul Janssens; Yanfei Guo
Journal:  Respir Res       Date:  2021-03-04

8.  C-Reactive Protein Concentrations Among Crop and Dairy Farmers with Stable Chronic Obstructive Pulmonary Disease.

Authors:  Saso Stoleski; Jordan Minov; Jovanka Karadzinska-Bislimovska; Dragan Mijakoski; Lütfiye Tutkun
Journal:  Open Access Maced J Med Sci       Date:  2017-09-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.